3 min read

FDA Finalizes Guidance On Registries’ Contributions to Regulatory Submissions

Read into the implications of the latest guidance from the FDA on utilizing registries.
Read into the implications of the latest guidance from the FDA on registries usefulness for various purposes and how to best build one.

FDA’s recently finalized its guidance document, Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products1, as part of its Real-World Evidence program. This guidance provides a brief overview of key factors when considering the use of registry data to evaluate a specific safety risk, to characterize long-term effectiveness outcomes, or to serve as an external control for an interventional study.  Strengths and limitations of registry data for these purposes are reviewed, reminding researchers of key epidemiologic principles such as representativeness of the registry population, data standardization and consistency, and understanding missing data and loss to follow-up. Important considerations for ensuring that a registry includes relevant and reliable data when designing a de novo registry as well as considerations when evaluating existing registries’ fitness for use in answering specific study objectives are noted. The guidance also provides a useful high-level list of important data elements integral to a robust registry.

UBC’s experience in designing and conducting disease and exposure registries, as well as integrating data from multiple sources for individual patients or from multiple registries to increase the power of a study, can provide deeper insights into the concepts highlighted by FDA in this guidance and assist Sponsors in the most efficient and effective ways to create and use registries.

ABOUT UBC:

UBC helps biopharma mitigate risk, address product hurdles, and demonstrate safety, efficacy, and value under real-world conditions. Bringing over 30 years of experience, UBC is uniquely positioned to develop end-to-end integrated evidence generation strategies, identify fit-for-purpose data sources, operationalize planned studies, and ensure regulatory-grade, publishable outputs.

ABOUT THE AUTHOR:

Annette Stemhagen, DrPH, FISPE

Dr Stemhagen, UBC’s Chief Scientific Officer, has a long history of registry involvement, having served as the Director of the New Jersey State Cancer Registry and the Principal Investigator for a National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) registry. She currently provides strategic consultative services and program oversight to pharmaceutical and biotech clients in epidemiology, safety surveillance, and risk management, focusing on observational research and real-world evidence. 

REFERENCE:

1. U.S. Food & Drug Administration. Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products. Guidance for Industry. December 2023. Accessed January 9, 2024. https://www.fda.gov/media/154449/download

Other Recent Posts

Press
5 min read

UBC Successfully Implemented REMS Administration Software DuringHL7® FHIR® Connectathon

UBC demonstrated our commitment to optimizing safe medication use and health outcomes by participating in the HL7® FHIR® Connectathon.
Press
5 min read

UBC Selects Oracle Cloud Safety Technology for its Safety Programs

UBC selected Oracle Life Sciences' safety case management solution.
Press
2 min read

UBC Receives CRO Leadership Award Again

UBC was honored as a winner in the 2023 CRO Leadership Awards by both big and small pharma in the Reliability category.

Thank You for Connecting with UBC

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

What You Can Expect Next

Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.

Get Ready to Change Your Business

Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.

Service Request

Bekki Bracken Brown

President & Chief Executive Officer

Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.

With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.